ArticleTherapeutic advances in hematology2025

BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study.

Sophie Dupuis-Girod et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.